These findings indicate that the relationship between adiponectin and all-cause mortality in CKD patients is significantly modulated by study site, dialysis modality, sex proportion, and BMI, with these factors accounting for much of the observed heterogeneity in the overall analysis. Here, ADIPOQ is linked to chronic kidney disease.